Gastrin-releasing peptide has long been held for its possible role as a target for inflammatory disease [156], including cardiovascular disease, gastrointestinal disease, pulmonary disease, and of course, its roles in endocrine disorders, namely glucose metabolism. Here, GRP is linked to lung disorder.